Aksamit TR, O'Donnell AE, Barker A, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest. 2017;151(5):982–92.
Article
Google Scholar
McShane PJ, Naureckas ET, Tino G, et al. Non–cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–56.
Article
Google Scholar
Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2015;127(4):1420–6.
Google Scholar
Haworth CS, Foweraker JE, Wilkinson P, et al. Inhaled Colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014;189(8):975–82.
Article
Google Scholar
Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non–cystic fibrosis bronchiectasis the BLESS randomized controlled trial. JAMA. 2013;309(12):1260–7.
Article
CAS
Google Scholar
Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non–cystic fibrosis bronchiectasis the BAT randomized controlled trial. JAMA. 2013;309(12):1251–9.
Article
CAS
Google Scholar
Chalmers JD, Aliberti S, Filonenko A, et al. Characterisation of the “frequent exacerbator phenotype” in bronchiectasis. Am J Respir Crit Care Med. 2018;197:1410–20.
Article
Google Scholar
Mogayzel, Jr PJ., Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7): 680–689.
Flume PA, Robinson KA, O'Sullivan BP, Finder JD, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009;54(4):522–37.
PubMed
Google Scholar
Fink JB. Forced expiratory technique, directed cough, and autogenic drainage. Respir Care. 2007;52(9):1210–23.
PubMed
Google Scholar
O'Donnell AE, Barker IJS, et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest. 1997;113(5):1329–34.
Article
Google Scholar
Wills PJ, Wodehouse T, Corkery K, et al. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. Am J Respir Crit Care Med. 1996;154(2 Pt 1):413–7.
Article
CAS
Google Scholar
Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006;354(3):241–25.
Article
CAS
Google Scholar
Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006;354(3):229–40.
Article
CAS
Google Scholar
Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med. 2005;99(1):27–31.
Article
CAS
Google Scholar
Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med. 2011;105(12):1831–5.
Article
Google Scholar
Nicolson CHH, Stirling RG, Borg BM, et al. The long-term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. 2012;106(5):661–7.
Article
Google Scholar
McIlwaine MP, Alarie N, Davidson GF, et al. Long-term multicentre randomised controlled study of high frequency Chest Wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax. 2013;68:746–51.
Article
Google Scholar
Nicolini A, Cardini F, Landucci N, et al. Effectiveness of treatment with high-frequency Chest Wall oscillation in patients with bronchiectasis. BMC Pulmonary Medicine. 2013;13:21.
Article
Google Scholar
Hill AT, Haworth CS, Aliberti S, et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. Eur Respir J. 2017;49(6):1700051.
Article
Google Scholar
Kempainen RR, Milla C, Dunitz J, Savik K, Hazelwood A, Williams C, et al. Comparison of settings used for high-frequency chest wall compression in cystic fibrosis. Respir Care. 2010;55(6):695701.
Google Scholar
Culver BH, Graham BL, Coates AL, et al. ATS Committee on proficiency standards for pulmonary function laboratories. Recommendations for a standardized pulmonary function report: an official American Thoracic Society technical statement. Am J Respir Crit Care Med. 2017;196:1463–72.
Article
Google Scholar
Chalmers JD, Restrepo MI. Bronchiectasis management the state of the union. Chest. 2017;152(6):1097–9.
Article
Google Scholar
Amalakuhan B, Maselli DJ, Martinez-Garcia MA. Update in bronchiectasis 2014. Am J Respir Crit Care Med. 2015;192:1155–61.
Article
Google Scholar
Pasteur MC, Bilton D, Hill AT, et al. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65:577.
Article
CAS
Google Scholar
Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50:1700629.
Article
Google Scholar
Chang AB, Bell SC, Torzillo PJ, et al. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Medical Journal of Australia. 201;202(3):130.
Welsh EJ, Evans DJ, Fowler SJ, et al. Interventions for bronchiectasis: an overview of Cochrane systemic reviews. Cochrane Database of systemic Reviews. 2015;7.
Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85.
Article
Google Scholar